These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 30543841)

  • 1. Standardizing CAR-T therapy: Getting it scaled up.
    Dai X; Mei Y; Cai D; Han W
    Biotechnol Adv; 2019; 37(1):239-245. PubMed ID: 30543841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
    Han C; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR-T cell and Personalized Medicine.
    Cruz-Ramos M; García-Foncillas J
    Adv Exp Med Biol; 2019; 1168():131-145. PubMed ID: 31713169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
    Siegler EL; Wang P
    Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?
    Salmikangas P; Kinsella N; Chamberlain P
    Pharm Res; 2018 May; 35(8):152. PubMed ID: 29855723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Making CAR T Cells a Solid Option for Solid Tumors.
    Schmidts A; Maus MV
    Front Immunol; 2018; 9():2593. PubMed ID: 30467505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of CAR-T Cells for Cancer Immunotherapy.
    Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
    Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives.
    Lee YH; Kim CH
    Arch Pharm Res; 2019 Jul; 42(7):607-616. PubMed ID: 30830661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric Antigen Receptor T Cell Immunotherapy for Tumor: A Review of Patent Literatures.
    Fu M; Tang L
    Recent Pat Anticancer Drug Discov; 2019; 14(1):60-69. PubMed ID: 30636615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
    Gowrishankar K; Birtwistle L; Micklethwaite K
    Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR T cells - what have we learnt?
    Nat Rev Clin Oncol; 2017 Dec; 15(1):1. PubMed ID: 29242589
    [No Abstract]   [Full Text] [Related]  

  • 16. CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy.
    Sacchetti B; Botticelli A; Pierelli L; Nuti M; Alimandi M
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives.
    Coscia M; Vitale C; Cerrano M; Maffini E; Giaccone L; Boccadoro M; Bruno B
    Front Biosci (Landmark Ed); 2019 Jun; 24(7):1284-1315. PubMed ID: 31136980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy.
    Han X; Wang Y; Wei J; Han W
    J Hematol Oncol; 2019 Nov; 12(1):128. PubMed ID: 31783889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
    Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
    Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring.
    Shao F; Long Y; Ji H; Jiang D; Lei P; Lan X
    Theranostics; 2021; 11(14):6800-6817. PubMed ID: 34093854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.